

1 **Identification of pathogens in culture-negative infective endocarditis cases by**
2 **metagenomic analysis**

3
4 Jun Cheng¹, Huan Hu^{1,2}, Yue Kang², Weizhi Chen², Wei Fang², Kaijuan Wang¹, Qian
5 Zhang³, Aisi Fu⁴, Shuilian Zhou², Chen Cheng², Qingqing Cao², Feiyan Wang^{1,*},
6 Shela Lee^{2,*}, Zhou Zhou^{1,*}

7
8 ¹State Key Laboratory of Cardiovascular Disease, Beijing Key Laboratory for
9 Molecular Diagnostics of Cardiovascular Diseases, Diagnostic Laboratory Service,
10 Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of
11 Medical Sciences and Peking Union Medical College, Beijing 100037, China

12 ²State Key Laboratory of Translational Medicine and Innovative Drug Development,
13 Sincere Diagnostics Co., Ltd., Nanjing 210042, China

14 ³Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular
15 Diseases, Chinese Academy of Medical Science and Peking Union Medical College,
16 Beijing 100037, China

17 ⁴Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of
18 Education and School of Pharmaceutical Sciences , Wuhan University , Wuhan
19 430071 , China

20

21 Authors email address:

22 Jun Cheng (jackcheng2001@163.com), Huan Hu (huhuan@simceredx.com), Yue
23 Kang (kangyue@simceredx.com), Weizhi Chen (chenweizhi@simceredx.com), Wei
24 Fang (fangwei@simceredx.com), Kaijuan Wang (wkaijuan@126.com), Qian
25 Zhang(nankedoudou@126.com), Aisi Fu (flashfas@whu.edu.cn), Shuilian Zhou
26 (zhoushuilian@simceredx.com), Chen Cheng (chengchen@simceredx.com),
27 Qingqing Cao (caoqingqing@simceredx.com), Feiyan Wang
28 (wang_feiyanfw@sina.com), Shela Lee (shela_lee@simceredx.com), Zhou Zhou
29 (zhouzhou@fuwaihospital.org)

30

31

32

33 *Corresponding authors:

34 Zhou Zhou (zhouzhou@fuwaihospital.org),

35 Telephone: 010-88398055

36 Fax numbers: 86-010-88398055

37

38 Shela Lee (shela_lee@simceredx.com),

39 Telephone: 025-85566666

40 Fax numbers: 025-85566666

41

42 Feiyan Wang (wang_feiyanfw@sina.com)

43 Telephone: 010-88398083

44 Fax numbers: 86-010-88396217

45

46 These authors contributed equally: Jun Cheng, Huan Hu, Yue Kang.

47

48 **Abstract**

49 Pathogens identification is critical for the proper diagnosis and precise treatment of
50 infective endocarditis. Although blood and valve cultures are the gold standard for IE
51 pathogens detection, many cases are culture-negative, especially in patients who had
52 received long-term antibiotic treatment, and precise diagnosis has therefore become a
53 major challenge in the clinic. Metagenomic sequencing can provide both information
54 on the pathogenic strain and the antibiotic susceptibility profile of patient samples
55 without culturing, offering a powerful method to deal with culture-negative cases. In
56 this work, we assessed the feasibility of a metagenomic approach to detect the
57 causative pathogens in resected valves from IE patients.

58 Using our in-house developed bioinformatics pipeline, we analyzed the sequencing
59 results generated from both next-generation sequencing and Oxford Nanopore
60 Technologies MinION nanopore sequencing for the direct identification of pathogens
61 from the resected valves of seven clinically culture-negative IE patients according to
62 the modified Duke criteria. Moreover, we were able to simultaneously characterize
63 respective antimicrobial resistance features. This provides clinicians with valuable
64 information to diagnose and treat IE patients after valve replacement surgery.

65 **Keywords:** metagenomic analysis; nanopore sequencing; next-generation sequencing
66 (NGS); infective endocarditis (IE)

67 **Introduction**

68 Infective endocarditis (IE) is a serious disease associated with significant morbidity
69 and mortality(1-3), whose prognosis strongly depends on early diagnosis and
70 optimized antibiotic therapy. Therefore, identifying the underlying pathogens
71 responsible for IE is critical. Currently, blood and valve cultures are the gold standard
72 for IE pathogens detection, but they are time-consuming and infeasible for fastidious
73 or intracellular microorganisms(4), which is a major clinical problem. Although
74 targeted amplicon sequencing such as 16S rRNA sequencing overcomes the
75 limitations of conventional culture-based methods, it can only be used to screen for
76 bacteria(5,6) and does not provide any antibiotic susceptibility information.

77 Rapid advancements in sequencing technologies provide us with new tools for
78 microbial identification without the need for culturing(7-9). The feasibility of direct
79 pathogens identification from IE samples by short-read whole-genome sequencing on
80 next-generation sequencing (NGS) platforms has been demonstrated in several
81 studies(10,11). Recently, an increased number of studies have shown promise for
82 metagenomics analysis using nanopore long-read sequencing in the rapid detection of
83 microorganisms in clinical samples, including virus from blood samples and bacteria
84 from urine samples(12-14)

85 To evaluate the analytical and clinical sensitivity and specificity of metagenomics
86 analysis in IE diagnosis, we analyzed the sequencing results generated from both
87 NGS and nanopore sequencing in this study. Sequencing platform-specific

88 bioinformatics pipelines were designed and developed in-house to identify pathogens
89 and detect antimicrobial resistance (AMR) in seven culture-negative IE patients.
90

91 **Materials and Methods**

92 **Sample collection and information**

93 The resected valves were collected from the Center of Cardiac Surgery in Fuwai
94 Hospital, National Center for Cardiovascular Diseases (Beijing, China), from April
95 2017 to August 2017. The study was approved by the ethics committee of the hospital.
96 All patients involved in this study provided their written informed consent, and
97 samples were used for research only. In our study, we included seven patients (six
98 men and one woman, Table S1). These patients were all diagnosed with definite IE
99 (D.IE) according to the modified Duke criteria. The specimens were cut into two
100 equal-sized pieces using sterile scissors in a biosafety cabinet. One piece of tissue was
101 randomly selected for immediate culturing, while the other was snap-frozen at -80°C
102 for metagenomic sequencing and Sanger validation.

103 **Valve culture (VC) and blood culture (BC)**

104 The specimens were physically ground into particles using a sterile grinder, then
105 placed in sterile tubes containing 5 ml of brain-heart infusion broth and incubated in a
106 CO₂ enriched atmosphere (5%) at 35°C for 7 days. Growth was evaluated daily. After
107 7 days of incubation, all samples were subcultured onto blood agar plates (Oxoid,
108 Beijing, China), chocolate agar plates (Oxoid) and MacConkey agar plates (Oxoid),
109 regardless of whether or not growth was suspected. An average of three sets of blood
110 samples were drawn by peripheral venous puncture prior to antibiotic use. Blood
111 samples (about 10 ml for adults, 1–3 ml for children) were injected into aerobic and

112 anaerobic blood culture bottles (Becton Dickinson, Sparks, MD, USA). Blood culture
113 bottles were then loaded into an automated continuous monitoring system (BD
114 BACTEC™ FX400, USA) within 1 h of being drawn and were incubated at 35°C for
115 7 days. If the subculture of the blood or valves showed bacterial growth, identification
116 was carried out by VITEK MALDI-TOF mass spectrometry (bioMérieux, Marcy
117 l'Étoile, France) and antibiotic susceptibility testing was performed subsequently with
118 VITEK 2 COMPACT (bioMérieux).

119 **DNA extraction and NGS with BGISEQ-500**

120 The frozen valves were thawed at room temperature for 30 min and were then cut into
121 pieces as small as possible with sterile scissors. Approximately 25 mg of tissue was
122 treated with proteinase K (No.148012595, Qiagen, Hilden, Germany) before DNA
123 extraction. Total DNA was extracted using a TIANamp Micro DNA kit (DP316,
124 Tiangen Biotech, Beijing, China) according to the manufacturer's recommendation.
125 The extracted DNA was fragmented with a Bioruptor (ThermoFisher Scientific,
126 Waltham, MA, USA) instrument to generate 200–300 bp fragments. Libraries were
127 then prepared as follows: first, the DNA fragments were subjected to end-repair and
128 A-tailing; second, the resulting DNA was ligated with bubble-adapters that contained
129 a barcode sequence, and then amplified with PCR. Quality control was carried out
130 with an Agilent 2100 (Agilent Technologies, Santa Clara, CA, USA) to assess the
131 fragment size and using a Qubit dsDNA HS Assay kit (ThermoFisher Scientific) to
132 measure the DNA library concentrations. Qualified libraries were pooled together to
133 form single-stranded DNA (ssDNA) circles and then DNA nanoballs were generated
134 with rolling circle replication. The final DNA nanoballs were loaded onto a
135 sequencing chip and were sequenced with a BGISEQ-500 platform (BGI-Tianjin).

136 Human sequence data were excluded by mapping to a human reference (hg19) using
137 the Burrows–Wheeler alignment tool. After removing human sequences, the
138 remaining sequencing data were aligned to four microbial genome databases,
139 consisting of viruses, bacteria, fungi and parasites. The mapped data were processed
140 for advanced data analysis. We downloaded the latest version of the microbial
141 reference genomes from NCBI (<ftp://ftp.ncbi.nlm.nih.gov/genomes/>). Currently, our
142 databases cover 1,428 bacterial species, 1,130 viral species related to human diseases,
143 73 fungal species related to human infections, and 48 parasites associated with human
144 diseases. We used the SOAP Coverage software from the SOAP website
145 (<http://soap.genomics.org.cn/>) to calculate the multi-parameters of the species.

146 **PCR and Sanger validation**

147 Extracted DNA of IE resected valves was simultaneously validated by Sanger
148 sequencing, using specific PCR primers: 5'-AGAGTTTGATCCTGGCTCAG-3' and
149 5'-GGTTACCTTGTTACGACTT-3'. PCR reactions were performed as follows: 96°C
150 for 150 s; (96°C, 30 s; 55°C, 30 s, and 72°C, 90 s) for 30 cycles, then 72°C for 7 min,
151 ending at 4°C. PCR products were detected by agarose gel electrophoresis and
152 purified with a gel extraction kit (DC3511-02, Biomiga Inc., San Diego, CA, USA).
153 Sanger sequencing was performed on an ABI PRISM 3730 DNA Sequencer (Applied
154 Biosystems, Foster City, CA, USA) for validation. Finally, the sequences were
155 analyzed for IE pathogens identification by alignment with sequences in the NT
156 database using the NCBI Blast online software
157 (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM5blastn&PAGE_TYPE5BlastSearch&LINK_LOC5blasthome).
158

159 **MinION library preparation and sequencing**

160 The frozen valves were thawed at room temperature for 30 min and were then cut into
161 pieces as small as possible with sterile scissors. Approximately 25 mg of tissue was
162 treated with proteinase K before DNA extraction. Total DNA was extracted using
163 QIAamp DNA Mini Kit (Cat No. 51304, Qiagen) according to the manufacturer's
164 recommendation. Library preparation was performed using the Ligation Sequencing
165 Kit (SQK-LSK108) and Native Barcoding Kit (EXP-NBD103) for genomic DNA,
166 according to the standard 1D Native barcoding protocol provided by the manufacturer
167 (Oxford Nanopore). Briefly, 1.2 µg of extracted genomic DNA from each resected
168 valve sample was fragmented with g-TUBE (Covaris) at 5,000 rpm for 1 min. To
169 perform end-repair, 45 µL of fragmented DNA was mixed in a 0.2 ml PCR tube with
170 3 µL of Ultra II End-prep enzyme mix (New England BioLabs, NEB), 7 µL of
171 Ultra II End-prep reaction buffer (NEB), and 5 µL of nuclease-free water. The
172 mixture was incubated at 20°C for 5 min, then at 65°C for 5 min. Next, 500 ng of
173 end-prepped samples were combined with 2.5 µL of Native Barcode (one barcode per
174 sample) and 25 µL of Blunt/TA Ligase Master Mix. The mixtures were incubated at
175 21°C for 30 min.

176 A total of 700 ng of barcoded libraries were pooled together with 20 µL of Barcode
177 Adapter Mix (BAM) and 10 µL of Quick T4 DNA ligase was added. The mixture was
178 incubated for 10 min at room temperature. The constructed library was loaded into the
179 Flow Cell R9.4 or R9.5 (FLO-MIN106 or FLO-MIN107) of a MinION device, which

180 was run with the SQK-LSK108_plus_Basecaller script of the MinKNOW1.7.14
181 software.

182 **Quality control analysis of the NGS data and nanopore data**

183 From the pair-end 150 bp sequence data generated from the BGI platform,
184 low-quality reads, adapter contamination, and duplicated reads and short reads (length
185 <35 bp) were removed. The remaining sequences were then used in further analysis.

186 For the sequencing data obtained from the Nanopore MinION sequencer, base-calling
187 tools in Albacore were used to base-call the data in fast5 files and de-multiplex the
188 data to fastq files for each sample. After quality control analysis, reads with lengths
189 longer than 500 bp and mean quality scores >6 were used in further analysis.

190 **Species identification of pathogens in seven clinical samples using NGS data and** 191 **nanopore data**

192 For species identification, first reads originating from the host genome were depleted.
193 In detail, after quality control analysis, reads were aligned with the human genome
194 GRCh38.p11 using bwa mem in the BWA software (genome download from
195 ftp://ftp.ncbi.nlm.nih.gov/genomes/all/GCA/000/001/405/GCA_000001405.26_GRC
196 h38.p11). Reads that could not be mapped to the human genome were retained and
197 aligned with the microorganism genome database for pathogens identification. Our
198 microorganism genome database contained genomic sequences from 259 bacteria,
199 5,591 fungi and 236 viruses, and sequences from 47 plasmids (plasmid sequences are
200 from <ftp://ftp.ncbi.nlm.nih.gov/genomes/refseq/plasmid>, and other sequences are from

201 <ftp://ftp.ncbi.nlm.nih.gov/genomes/all/>). A k-mer alignment algorithm named
202 Centrifuge(15) was used to identify the pathogens in each sample. Species with
203 identified reads ≤ 2 for nanopore data and ≤ 10 for NGS data were removed, and for
204 those remaining, the relative enrichment rate by query length was calculated and
205 normalized according to genome size. Species with a relative enrichment rate $>20\%$
206 were reported, whereas species with a relative enrichment rate $>0.2\%$ and $<20\%$ were
207 analyzed further by sampling 200 reads to verify the identify accuracy by blastn(16)in
208 the NT database. Verified species were reported. Finally, all species in the report list
209 were re-calculated for their relative enrichment rate.

210 **AMR detection among the identified IE pathogens using NGS and nanopore**

211 **data**

212 After species identification, reads that could not be mapped in the human genome
213 were used for AMR analysis. Species identification tags were added and reads were
214 aligned in the AMR database CARD(17)by Blastn. For all query results, hits with
215 blast e-values $<e^{-30}$ were picked for further analysis. For AMR gene tracking, when
216 sequences were aligned, if hits were lacking in the 5' or 3' regions of the gene but
217 coverage of the central part of the gene was observed that would be sufficient to be
218 reported as an AMR gene. For the nanopore data, because of the long read lengths,
219 support from one read was acceptable, but support from three reads was needed for
220 the NGS data. For AMR SNP sites, the coverage level for the gene in which the SNP
221 was located was required to be the same as that from which the AMR gene was

222 detected. Furthermore, each SNP site required support from more than two reads for
223 the nanopore data and three reads for the NGS data. After data had been obtained for
224 AMR genes and SNP sites, the results were organized by drug resistance type using
225 the annotation in the CARD database. Finally, species identification tags were used to
226 map AMR genes to the species level.
227

228 **Results**

229 **Clinical characteristics and diagnosis of seven IE patients**

230 To assess the feasibility of metagenomic analysis in the identification of IE pathogens,
231 seven IE patients were included in this study, with most of these patients being male
232 (n=6, 85.7%) with a mean age of 48.3 (Table S2). Our strategy was to employ NGS
233 and nanopore sequencing-based metagenomics analysis to identify IE pathogens with
234 verification provided by Sanger sequencing and traditional clinical diagnosis methods
235 (Fig 1 and Fig 2).

236 The patients were firstly scheduled for systemic examinations in the hospital and all
237 were clinically diagnosed as definite cases of IE according to the modified Duke
238 criteria (Fig 1 and Table 1). Most of the blood culture results were negative (n=5)
239 except for *Streptococcus oralis* detected in patient A5 and *Streptococcus anginosus*
240 detected in patient A7 (Table 1). Valve replacement surgeries were then performed
241 and the resected valves were used for Gram-staining and culturing. All of the valve
242 culture results were negative except for one, which was considered to be due to
243 contamination (Table 1).

244 **NGS-based metagenomic analysis for the detection of IE pathogens**

245 Resected valves were then used for metagenomics analysis based on NGS. The total
246 DNA of each patient's valve was extracted and then fragmented to generate 200–
247 300-bp fragments, which were used to construct a library according to the
248 manufacturer's protocol (BGI-Tianjin, Tianjin, China; see details in the Materials and

249 Methods section). The final library was sequenced using the BGISEQ-500 platform to
250 generate sequencing data.

251 After analyzing the data for quality control, the remaining fastq reads for each sample
252 were collected with data volumes of 4.1G (A1), 17G (A2), 3.3G (A3), 4.4G (A4),
253 8.8G (A5), 3.1G (A6), and 6G (A7). These data were then subjected to bioinformatic
254 analysis to detect pathogen species and AMR genes (see details in the Materials and
255 Methods section).

256 Metagenomic analysis of the NGS data generated reads of the possible IE pathogens
257 detected for all seven samples (4,260 reads of *Streptococcus gordonii* for A1, 25,275
258 reads of *S. oralis* for A2, 3,921 reads of *Coxiella burnetii* for A3, 29,438 reads of
259 *Bartonella quintana* for A4, 54,881 reads of *S. oralis* for A5, 370 reads of
260 *Streptococcus sanguinis* for A6, and 45,880 reads of *S. anginosus* for A7) (Table 2).

261 Other information such as pathogen coverage and the depth of the NGS sequencing
262 data were also analyzed (Fig 3A, S1A, and Table 2). Because the AMR profile of an
263 IE pathogens provides valuable information that can guide treatment, a specific
264 bioinformatics pipeline was developed to detect the AMR genes present in these
265 bacteria (Fig 2 and Table 3, S3).

266 **Nanopore sequencing-based metagenomic analysis for IE pathogens detection**

267 To evaluate the application of nanopore sequencing-based metagenomics analysis in
268 IE pathogens detection, DNAs from the seven resected valves were sequenced using
269 the MinION system. In brief, 1.2 µg of genomic DNA from each sample was

270 fragmented with g-TUBE and a library was prepared using the Ligation Sequencing
271 Kit and the Native Barcoding Kit (see details in the Materials and Methods section).
272 The sequencing data generated by the MinION system had a quality score of around
273 15. This quality score can be influenced by the quality of DNA samples multiplexed
274 in the same flow cell, and high quality multiplexed DNA samples generate larger data
275 with a higher quality score. For every sequencing read, the quality of the first 10 bases
276 can be unstable, with all subsequent bases having a consistent quality score, even for
277 the end bases of an ultra-long read. Reads longer than 1 kb with an average quality
278 score >7, were used in further bioinformatic analyses (see details in the Materials and
279 Methods section).

280 As a result of metagenomic analysis of the nanopore data, reads of the same IE
281 pathogens were also detected for all samples with NGS (23 and 16 reads of *S.*
282 *gordonii* for A1.1 and A1.2, 13 and 23 reads of *S. oralis* for A2.1 and A2.2, 68 reads
283 of *C. burnetii* for A3, 2,081 reads of *B. quintana* for A4, 302 reads of *S. oralis* for A5,
284 42 reads of *S. sanguinis* for A6, and 3,302 reads of *S. anginosus* for A7) (Table 4).
285 Other information such as pathogen coverage, depth, and read length of the nanopore
286 sequencing data were also analyzed (Fig 3B, S1B, and Table S4) with AMR genes of
287 these pathogens detected by the specific bioinformatics pipeline (Fig 2 and Table 3,
288 S3).

289 As a real-time sequencing platform, data produced by the MinION system can be
290 base-called and analyzed along with sequencing data. Data generation was rapid

291 during the initiation of sequencing, but decreased with time. After 10 h, negative
292 growth of data was noted. The real-time sequencing properties of the MinION device
293 enabled real-time analysis of pathogens detection, and the minimum stable detection
294 time for a pathogen could be altered by using different detection parameters. For
295 example, if the reads detection cutoff was set at two reads, pathogens in all samples
296 could be detected within 1 h (Fig 4 and Table S5).

297 Our results indicated that by integrating real-time nanopore sequencing and
298 appropriate metagenomic bioinformatic approaches, pathogens identification along
299 with the detection of AMR genes could be achieved in cases of culture-negative IE.

300

301 **Discussion**

302 Precise diagnosis and effective treatment of IE relies on the rapid and accurate
303 identification of its underlying pathogens. Although blood and valve cultures are the
304 gold standard for IE pathogens detection, blood culture-negative IE can occur in up to
305 31% of all cases(18).

306 In this work, we employed both NGS and Oxford Nanopore Technologies MinION
307 nanopore sequencing for pathogens and AMR detection in seven culture-negative IE
308 patients. Our results showed that both methods can reliably identify the causative
309 pathogen in all seven samples in accordance with the results of Sanger sequencing,
310 with the exception of one case in which Sanger sequencing failed (Table 1). Moreover,
311 in the case A2 and A5, Sanger sequencing could only identify bacteria to the genus
312 level whereas NGS and nanopore sequencing-based metagenomics analysis could
313 further classify bacteria to the species level.

314 Both the NGS and nanopore sequencing results were in agreement in terms of the top
315 enriched species across all samples; however, the remaining species identified were
316 not concordant between the two methods. The NGS results identified a significantly
317 higher number of different bacteria in each sample (Tables S6 and S7). The difference
318 in the amount of sequencing data generated from these two sequencing platforms
319 might contribute to this observation, with a total of 46 Gb of data generated by BGI
320 and only 15 Gb of data generated by MinION for all seven IE samples. Many species
321 identified using the NGS short-reads were of the same genus (Table S6). For example,

322 all nine species detected in A1 belonged to the genus *Streptococcus*, and all 11
323 species in A2 also belonged to *Streptococcus*. Therefore, we concluded that the
324 long-reads generated by nanopore sequencing increased the specificity of species
325 identification, whereas short-reads generated by NGS had lower resolution within
326 highly homologous species.

327 For AMR analysis, the extensiveness of pathogen genome coverage was critical.
328 AMR-related genes accounted for only about 1% of the bacterial genome, so broader
329 coverage meant a higher chance of detection. The BGI NGS platform had a much
330 higher data output than the MinION system, resulting in more comprehensive
331 pathogen genome coverage. Therefore, more AMR features were detected using NGS
332 sequencing compared with nanopore sequencing in our study. In terms of the AMR
333 genes detected by both platforms, the NGS results were supported by a significantly
334 higher depth of coverage, which improved the confidence associated with the
335 conclusions drawn from these data. However, the short-reads generated by NGS
336 limited the ability to deduce the origin of AMR genes, i.e. it was not possible to
337 determine the identity of the bacteria carrying a particular AMR feature. If a
338 comparable amount of data can be generated on the nanopore sequencing platform, it
339 offers the advantage of long-reads, which would aid the detection of AMR gene
340 origins. One challenge of AMR detection is to tag the AMR genes to specific microbe
341 because of the high homology of one AMR gene from different species. Sequencing
342 method with longer reads and bigger data volume will favor this goal. In most

343 culture-negative cases, clinicians may have to rely on trial and error during treatment,
344 whereas metagenomic methods can provide pathogens and AMR information, helping
345 to guide clinical drug usage. However, it may be necessary to construct clinic-specific
346 AMR libraries to aid the detection of AMR features.

347 A few other challenges were observed when analyzing nanopore sequencing data.
348 Sample barcoding is a common practice during library preparation to improve
349 sequencing cost effectiveness by multiplexing samples on one sequencing run. For
350 example, in this study, we multiplexed 3–6 samples for sequencing. Barcode leaking
351 occurred during de-multiplexing when a barcode was misidentified due to a
352 sequencing error. Although barcode leaking is a common problem shared by both
353 NGS and nanopore sequencing platforms, it was much more apparent in the nanopore
354 sequencing results due to its lower sequencing accuracy (advertised base call accuracy
355 of 99.9% for NGS versus 93% for nanopore 1D sequencing). Therefore, to eliminate
356 the possibility of sample cross-contamination on the nanopore sequencing platform,
357 sample multiplexing is not recommended, especially when analyzing clinical samples.
358 The ideal solution in clinical settings is to sequence only one sample per flow cell;
359 this not only avoids contamination but also addresses the clinical point-of-care
360 turnaround time by circumventing the need to batch samples.

361 Another major challenge in the metagenomic analysis of clinical samples is the high
362 percentage of host genome. More than 95% of sequencing data mapped to the host
363 (human) genome in most IE samples (Table S8), which translates to a huge waste of

364 sequencing data; only approximately 5% of the total sequencing data is actually
365 useable in pathogens identification and AMR detection. Development of appropriate
366 host depletion methods before library preparation will be critical to resolve this
367 problem and increase the percentage of useful sequencing data while maintaining the
368 same amount of total sequencing output, thereby improving detection sensitivity.

369 In conclusion, the advantages of NGS included low cost, large data volume, and high
370 accuracy rate. In metagenomic analysis, a higher sequencing output correlated with
371 increased sensitivity in pathogens identification and increased confidence in AMR
372 detection. However, the short read-length of NGS was a limiting factor for species
373 identification. For Oxford Nanopore Technologies MinION sequencing, higher cost
374 and lower sequencing data output were limitations in clinical application. However,
375 its unique physical properties and technical features were promising in terms of
376 clinical point-of-care applications. The small size of the device, simple library
377 preparation workflow, real-time sequencing data generation and analysis, and most
378 importantly, long read-length, provided higher accuracy in terms of species
379 identification and AMR linkage.

380 Our results indicated that the MinION device-based unbiased metagenomic detection
381 of IE pathogens from clinical samples could be performed with a sample-to-answer
382 turnaround time of <1 h if two reads were used as the cutoff and <4 h if five reads
383 were used as the cutoff for species identification. Furthermore, real-time
384 bioinformatic analysis was feasible using nanopore sequencing. All of these features

385 indicated the promising clinical applications of nanopore sequencing-based
386 metagenomic analysis, which were not limited to IE pathogens detection.

387 Compared with conventional clinical methods, there were some advantages of NGS
388 and nanopore sequencing metagenomic analysis in detecting microorganisms of IE.
389 First, metagenomics analysis could detect unculturable pathogens and overcome the
390 limitations of conventional culture-based methods. Second, metagenomics analysis
391 could detect different types of microorganisms including bacteria, viruses and fungi,
392 whereas 16S rRNA sequencing was limited to screen for bacteria.

393 Although there are some reports that used NGS-based metagenomic analysis to
394 identify the causative pathogens in culture-negative IE cases⁹, few of these evaluated
395 the usefulness of this new method in AMR gene detection. In this research, we
396 demonstrated that both NGS and nanopore sequencing-based metagenomic analysis
397 could be applied to identify the causative pathogens of IE, thereby providing a
398 valuable, supplemental tool for clinical diagnosis, especially in culture-negative cases.
399 However, before applying metagenomics analysis to clinical microorganism detection,
400 further studies are required to optimize protocols for sample processing, sequencing
401 and bioinformatics analysis.

402

403

404

405 **Acknowledgements**

406 This work was financially supported by Innovation Project for Medicine and Health
407 Science and Technology from the Chinese Academy of Medical Sciences (Research
408 Project Number:2016-I2M-1-016).

409

410 **Conflict of interests**

411 The authors declare that they have no conflict of interest.

412

413 **Author Contributions**

414 Z.Z, Shela Lee and F.W. conceived the idea; J.C., H.H. and W.C. designed the
415 experiments; J.C., H.H., K.W., S.Z., C.C. and Q.C. performed experiments and Y.K.
416 and W.F. analyzed data; J.C. and Q.Z. collected clinical samples. H.H., J.C. and Y.K.
417 wrote the manuscript; Z.Z, Shela Lee, F.W. and A.F. revised the manuscript. All
418 authors read and approved the final manuscript.

419

420 **References**


- 421 1. Thuny F, Grisoli D, Collart F, Habib G, Raoult D. 2012. Management of infective
422 endocarditis: Challenges and perspectives. *The Lancet*. 379: 965–
423 975 .[https://doi.org/10.1016/S0140-6736\(11\)60755-1](https://doi.org/10.1016/S0140-6736(11)60755-1)
- 424 2. Østergaard L, Valeur N, Ihlemann N, Bundgaard H, Gislason , Torp-Pedersen C,
425 Bruun NE, Søndergaard L, Køber L, Fosbøl EL. 2018. Incidence of infective
426 endocarditis among patients considered at high risk. *Eur Heart J*. 39:623-629.
427 <https://doi.org/10.1093/eurheartj/ehx682>
- 428 3. Hoen B, Duval X. 2013. Infective Endocarditis. *N Engl J Med*. 369:784-785.
429 <https://doi.org/10.1056/NEJMc1307282>
- 430 4. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru
431 R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price
432 S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta
433 I, Zamorano JL; ESC Scientific Document Group. 2015. 2015 ESC Guidelines for
434 the management of infective endocarditis: The Task Force for
435 the Management of Infective Endocarditis of
436 the European Society of Cardiology (ESC). *Eur Heart*
437 *J*. 36:3075-3128. <https://doi.org/10.1093/eurheartj/ehv319>
- 438 5. Breitkopf C, Hammel D, Scheld HH, Peters G, Becker K. 2005. Impact of a
439 molecular approach to improve the microbiological diagnosis of infective heart
440 valve

- 441 endocarditis.Circulation.111:1415-1421.<https://doi.org/10.1161/01.CIR.00001584>
- 442 81.07569.8D
- 443 6. Shah, N., Tang, H., Doak, T. G. & Ye, Y. 2011.Comparing bacterial communities
- 444 inferred from 16S rRNA gene sequencing and shotgun metagenomics. Pac Symp
- 445 Biocomput.165–176. https://doi.org/10.1142/9789814335058_0018
- 446 7. Hasman H, Saputra D, Sicheritz-Ponten T, Lund O, Svendsen CA, Frimodt-Møller
- 447 N, Aarestrup FM.. Rapid whole-genome sequencing for detection and
- 448 characterization of microorganisms directly from clinical samples.2014. J Clin
- 449 Microbiol. 52: 139–146 . <https://doi.org/10.1128/JCM.02452-13>
- 450 8. Guan H, Shen A, Lv X, Yang X, Ren H, Zhao Y, Zhang Y, Gong Y, Ni P, Wu
- 451 H, Zhu Y, Cui L. 2016.Detection of virus in CSF from the cases with
- 452 meningoencephalitis by next-generation sequencing. J Neurovirol.
- 453 22:240-245.<https://doi.org/10.1007/s13365-015-0390-7>
- 454 9. Long Y, Zhang Y, Gong Y, Sun R, Su L, Lin X, Shen A, Zhou J, Caiji Z, Wang
- 455 X, Li D, Wu H, Tan H.2016. Diagnosis of Sepsis with Cell-free DNA by
- 456 Next-Generation Sequencing Technology in ICU Patients. Arch Med Res. 47:365–
- 457 371. <https://doi.org/10.1016/j.arcmed.2016.08.004>
- 458 10. Fukui Y, Aoki K, Okuma S, Sato T, Ishii Y, Tateda K.2015. Metagenomic analysis
- 459 for detecting pathogens in culture-negative infective endocarditis. J Infect
- 460 Chemother. 21:882–884. <https://doi.org/10.1016/j.jiac.2015.08.007>
- 461 11. Imai A, Gotoh K, Asano Y, Yamada N, Motooka D, Fukushima M, Kanzaki

- 462 M, Ohtani T, Sakata Y, Nishi H, Toda K, Sawa Y, Komuro I, Horii T, Iida
463 T, Nakamura S, Takashima S. 2014. Comprehensive metagenomic approach for
464 detecting causative microorganisms in culture-negative infective endocarditis.
465 International Journal of
466 Cardiology.172:e288-9.<https://doi.org/10.1016/j.ijcard.2013.12.197>
- 467 12. Gong L, Huang YT, Wong CH, Chao WC, Wu ZY, Wei CL, Liu PY.
468 2018. Culture-independent analysis of liver abscess using nanopore sequencing.
469 PLoS One. 13: e0190853.<https://doi.org/10.1371/journal.pone.0190853>
- 470 13. Greninger AL, Naccache SN, Federman S, Yu G, Mbala P, Bres V, Stryke
471 D, Bouquet J, Somasekar S, Linnen JM, Dodd R, Mulembakani P, Schneider
472 BS, Muyembe-Tamfum JJ, Stramer SL, Chiu CY. 2015. Rapid metagenomic
473 identification of viral pathogens in clinical samples by real-time nanopore
474 sequencing analysis. Genome Med. 7:99.
475 <https://doi.org/10.1186/s13073-015-0220-9>
- 476 14. Li R, Xie M, Dong N, Lin D, Yang X, Wong MHY, Chan EW, Chen S. Efficient
477 generation of complete sequences of MDR-encoding plasmids by rapid assembly
478 of MinION barcoding sequencing
479 data.2018. Gigascience .7:1-9 .<https://doi.org/10.1093/gigascience/gix132>
- 480 15. Kim D, Song L, Breitwieser FP, Salzberg SL.2016. Centrifuge: rapid and accurate
481 classification of metagenomic sequences. Genome Res.26:1721-1729.
482 <https://doi.org/10.1101/gr.210641.116>

- 483 16. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local
484 alignment search tool. *J Mol Biol.* 215:403–410.
485 [https://doi.org/10.1016/S0022-2836\(05\)80360-2](https://doi.org/10.1016/S0022-2836(05)80360-2)
- 486 17. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, Bhullar
487 K, Canova MJ, De Pascale G, Ejim L, Kalan L, King AM, Koteva K, Morar
488 M, Mulvey MR, O'Brien JS, Pawlowski AC, Piddock LJ, Spanogiannopoulos
489 P, Sutherland AD, Tang I, Taylor PL, Thaker M, Wang W, Yan M, Yu T, Wright
490 GD. 2013. The comprehensive antibiotic resistance database. *Antimicrob Agents
491 Chemother.* 57:3348–3357. <https://doi.org/10.1128/AAC.00419-13>
- 492 18. Wallet F, Herwegh S, Decoene C, Courcol RJ. 2013.
493 PCR-electrospray ionization time-of-flight mass spectrometry: a new tool for
494 the diagnosis of infective endocarditis from heart valves. *Diagn Microbiol Infect
495 Dis.* 76:125-128. <https://doi.org/10.1016/j.diagmicrobio.2013.02.007>
496


497 **Figure legends**



498 **FIG 1:** Workflow of IE patient diagnosis with traditional clinic methods and

499 sequencing methods.

500




501


502 **FIG 2:**The bioinformatics pipeline for NGS and nanopore sequencing

503 metagenomic analysis.

A



B



504

505

506 **FIG 3:** Pathogen coverage of A1 and A2 sequencing data with both NGS and

507 Nanopore MinION platforms. A) the coverage density plot in detected pathogen

508 genome for NGS sequence from BGI platform of A1 and A2 samples; B) the

509 coverage density plot in detected pathogen genome for nanopore sequence from BGI

510 platform of A1 and A2 samples, each sample has two replications. For A1 sample, the

511 detected pathogen is *Streptococcus gordonii* (NC_009785.1). For A2 sample, the

512 detected pathogen is *Streptococcus oralis* (NC_015291.1).

513

514

515

516

517

518

519


520

521

522

523

524



525

FIG 4: Stable pathogen detection time for different cutoff of reads number in

526

nanopore sequencing data. X axis is the time for sequencing. Y axis is number of

527

reads for detected pathogen in the scale of \log_2 transfer. Three red dashed lines

528

are the cutoff for pathogen detection, corresponding for difference strict level as

529

two reads, five reads and ten reads. When set two reads as the detection cutoff, all

530

pathogens in samples will be detected within 1 h. Even use a higer cutoff (five

531

reads), all pathogens in samples will be detected within 4 h.

532

533 **Tables**

534 **TABLE 1.** Clinical diagnosis and Main laboratory results.

	Diagnosis	Valve gram staining	Blood culture	Valve culture	Nanopore	NGS	Sanger
A1	Definite IE ^a	GPC ^b	negative	<i>Filamentous fungi</i> ^c	<i>S. gordonii</i>	<i>S. gordonii</i>	<i>S. gordonii</i>
A2	Definite IE ^a	GPC ^b	negative	negative	<i>S.oralis</i>	<i>S.oralis</i>	<i>S.viridans spp</i>
A3	Definite IE ^a	negative	negative	negative	<i>Coxiellaburnetii</i>	<i>Coxiellaburnetii</i>	<i>Not detected</i>
A4	Definite IE ^a	negative	negative	negative	<i>Bartonella Quintana</i>	<i>Bartonella Quintana</i>	<i>Bartonella Quintana</i>
A5	Definite IE	negative	<i>S.oralis</i>	negative	<i>S.oralis</i>	<i>S.oralis</i>	<i>S.viridans spp</i>
A6	Definite IE ^a	GPC ^b	negative	negative	<i>S.sanguis</i>	<i>S.sanguis</i>	<i>S.sanguis</i>
A7	Definite IE	GPC ^b	<i>S.anginosus</i>	negative	<i>S.anginosus</i>	<i>S.anginosus</i>	<i>S.anginosus</i>

535 ^aDefinite IE was diagnosed according to histopathologic examination, clinical
 536 presentation and echocardiographic result.

537 ^bGPC, gram positive coccus.

538 ^cThis result was considered to be contamination.

539

540 **TABLE 2.** Detail of the results for pathogen species identification from NGS (BGI)
541 data.

Sample ID	Pathogen species	Genome size	Reads num	Unique reads num	Relative abundance	Coverage	Depth
A1	Streptococcus gordonii	2196662	4465	4260	82.40%	21.33%	1.4380
A2	Streptococcus oralis	1958690	31754	25275	81.01%	68.50%	3.5609
A3	Coxiella burnetii	1995488	4014	3921	100.00%	20.32%	1.1890
A4	Bartonella quintana	1581384	29676	29438	99.55%	77.68%	2.9408
A5	Streptococcus oralis	1958690	68435	54881	81.74%	75.74%	6.8056
A6	Streptococcus sanguinis	2388435	380	370	86.20%	2.33%	1.0434
A7	Streptococcus anginosus	2233640	47829	45880	87.82%	61.85%	5.1198

542

543

544

545 **TABLE 3.** AMR analysis results from two different platform sequencing data sets.

Drug	Platform	Sample ID			
		A1	A2	A5	A7
Tetracycline	BGI	-	tetM	tetM	tetM
	Nanopore	-	-	-	tetM
Macrolide	BGI	-	ErmB,RlmA(II)	ErmB,RlmA(II)	ErmB
	Nanopore	-	-	ErmB	ErmB
Lincosamide	BGI	-	ErmB,RlmA(II)	ErmB,RlmA(II)	ErmB
	Nanopore	-	-	ErmB	ErmB
Streptogramin	BGI	-	ErmB	ErmB	ErmB
	Nanopore	-	-	ErmB	ErmB
Fluoroquinolone	BGI	-	patB	patB,pmrA	-
	Nanopore	-	-	-	-

546 - No results for this kind of drug.

547

548

549

550

551 **TABLE 4.** Detail of the results for pathogen species identification from nanopore
552 data with seven samples.

Sample ID	Pathogen species	Genome size	Reads num	Unique reads num	Query length	Relative abundance	Coverage	Depth
A1.1	Streptococcus gordonii	2196662	24	23	25269	100.00%	1.11%	1.009
A1.2	Streptococcus gordonii	2196662	16	16	22003	100.00%	0.95%	1.000
A2.1	Streptococcus oralis	1958690	13	13	22945	100.00%	1.08%	1.022
A2.2	Streptococcus oralis	1958690	25	23	19502	100.00%	1.18%	1.016
A3	Coxiella burnetii	1995488	68	68	67040	100.00%	2.72%	1.057
A4	Bartonella quintana	1581384	2106	2081	3099223	100.00%	81.75%	2.091
A5	Streptococcus oralis	1958690	317	302	601776	94.72%	23.95%	1.165
A6	Streptococcus sanguinis	2388435	42	42	76221	100.00%	3.02%	1.056
A7	Streptococcus anginosus	2233640	3379	3302	4221132	90.77%	66.98%	2.755

553